Cargando…

Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application

Induced pluripotent stem cell (iPSC) technology has shown us great hope to treat various human diseases which have been known as untreatable and further endows personalized medicine for future therapy without ethical issues and immunological rejection which embryonic stem cell (hES) treatment has fa...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Changsung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974965/
https://www.ncbi.nlm.nih.gov/pubmed/24724061
http://dx.doi.org/10.5045/br.2014.49.1.7
_version_ 1782310075060191232
author Kim, Changsung
author_facet Kim, Changsung
author_sort Kim, Changsung
collection PubMed
description Induced pluripotent stem cell (iPSC) technology has shown us great hope to treat various human diseases which have been known as untreatable and further endows personalized medicine for future therapy without ethical issues and immunological rejection which embryonic stem cell (hES) treatment has faced. It has been agreed that iPSCs knowledge can be harnessed from disease modeling which mimics human pathological development rather than trials utilizing conventional rodent and cell lines. Now, we can routinely generate iPSC from patient specific cell sources, such as skin fibroblast, hair follicle cells, patient blood samples and even urine containing small amount of epithelial cells. iPSC has both similarity and dissimilarity to hES. iPSC is similar enough to regenerate tissue and even full organism as ES does, however what we want for therapeutic advantage is limited to regenerated tissue and lineage specific differentiation. Depending on the lineage and type of cells, both tissue memory containing (DNA rearrangement/epigenetics) and non-containing iPSC can be generated. This makes iPSC even better choice to perform disease modeling as well as cell based therapy. Tissue memory containing iPSC from mature leukocytes would be beneficial for curing cancer and infectious disease. In this review, the benefit of iPSC for translational approaches will be presented.
format Online
Article
Text
id pubmed-3974965
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-39749652014-04-10 Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application Kim, Changsung Blood Res Review Article Induced pluripotent stem cell (iPSC) technology has shown us great hope to treat various human diseases which have been known as untreatable and further endows personalized medicine for future therapy without ethical issues and immunological rejection which embryonic stem cell (hES) treatment has faced. It has been agreed that iPSCs knowledge can be harnessed from disease modeling which mimics human pathological development rather than trials utilizing conventional rodent and cell lines. Now, we can routinely generate iPSC from patient specific cell sources, such as skin fibroblast, hair follicle cells, patient blood samples and even urine containing small amount of epithelial cells. iPSC has both similarity and dissimilarity to hES. iPSC is similar enough to regenerate tissue and even full organism as ES does, however what we want for therapeutic advantage is limited to regenerated tissue and lineage specific differentiation. Depending on the lineage and type of cells, both tissue memory containing (DNA rearrangement/epigenetics) and non-containing iPSC can be generated. This makes iPSC even better choice to perform disease modeling as well as cell based therapy. Tissue memory containing iPSC from mature leukocytes would be beneficial for curing cancer and infectious disease. In this review, the benefit of iPSC for translational approaches will be presented. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014-03 2014-03-24 /pmc/articles/PMC3974965/ /pubmed/24724061 http://dx.doi.org/10.5045/br.2014.49.1.7 Text en © 2014 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Changsung
Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title_full Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title_fullStr Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title_full_unstemmed Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title_short Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application
title_sort disease modeling and cell based therapy with ipsc: future therapeutic option with fast and safe application
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974965/
https://www.ncbi.nlm.nih.gov/pubmed/24724061
http://dx.doi.org/10.5045/br.2014.49.1.7
work_keys_str_mv AT kimchangsung diseasemodelingandcellbasedtherapywithipscfuturetherapeuticoptionwithfastandsafeapplication